This Poop 'Cure' May Have Unintended Long-Term Effects, Study Finds
Researchers have seen promising signs of its ability to address irritable bowel syndrome, Crohn's disease, and even early Parkinson's (though this benefit only seemed to be short-lived) and other neurological issues.
It has a 90% success rate for treating C.diff, a bacterium related to diarrhoea, the BBC reported.
But a new study published in the journal Cells has raised questions about the long-term safety of FMT treatments, suggesting that a bacterial 'mismatch' may cause problems with the patient's immune system and metabolism down the line.
The scientists only found the link in mice and were not able to say how the changes they witnessed in the animals might manifest in people.
They gave antibiotics to mice to interrupt their gut's normal microbiome, and then treated them with FMT and monitored them for one to three months.
Often, the researchers discovered, the gut bacteria ended up in the wrong part of the gut – 'regional mismatches' – that seemed to disrupt the gut.
After taking biopsies of the liver and gut, the scientists found that some genes, especially those related to the immune system and metabolism, had changed.
Speaking to the University of Chicago, the study's lead author, researcher Orlando 'Landon' DeLeon said: 'I think it's a bit of a wake-up call to the field that maybe we shouldn't willy-nilly put large bowel microbes into different parts of the intestine that shouldn't be there.
'There are microbes along the entire intestinal tract, and we just study predominantly the last third of it (the colon),' he added. 'So how can you expect an FMT, with microbes from a third of the intestinal tract at the end of it, to fix the rest of the intestine?'
No. This study was done on mice, which have different anatomies from us; even though the scientists found genetic changes in the liver and gut, they are not sure yet how those changes might affect even the mouse, never mind us.
The study's researchers, however, still think it's a good idea to pursue 'omni-microbial transplants,' or OMT, writing in their paper: 'regional microbial mismatches after FMTs can lead to unintended consequences and require rethinking of microbiome-based interventions.'
OMTs would include more bacteria from a greater area of the gut, theoretically increasing the likelihood that the correct ones will go to the right spot.
Gut Health Discovery Could Help Future Parkinson's Diagnoses
Let's Settle This – Is The Viral 'Puff Vs Pit' Armpit Health Check Actually Helpful?
New Study Finds The Exact Age Bad Health Habits Catch Up To You
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio
CNN
26 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.
CNN
27 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.
